230 related articles for article (PubMed ID: 32245893)
1. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
Hsieh PH; Wu O; Geue C; McIntosh E; McInnes IB; Siebert S
Ann Rheum Dis; 2020 Jun; 79(6):771-777. PubMed ID: 32245893
[TBL] [Abstract][Full Text] [Related]
2. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
Her M; Kavanaugh A
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
[TBL] [Abstract][Full Text] [Related]
3. Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment-A Systematic Literature Review.
Batko B; Rolska-Wójcik P; Władysiuk M
Int J Environ Res Public Health; 2019 Aug; 16(16):. PubMed ID: 31426543
[TBL] [Abstract][Full Text] [Related]
4. Evolution of cost structures in rheumatoid arthritis over the past decade.
Huscher D; Mittendorf T; von Hinüber U; Kötter I; Hoese G; Pfäfflin A; Bischoff S; Zink A;
Ann Rheum Dis; 2015 Apr; 74(4):738-45. PubMed ID: 24406543
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
6. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the economic burden of productivity loss in rheumatoid arthritis.
Filipovic I; Walker D; Forster F; Curry AS
Rheumatology (Oxford); 2011 Jun; 50(6):1083-90. PubMed ID: 21245074
[TBL] [Abstract][Full Text] [Related]
8. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
[TBL] [Abstract][Full Text] [Related]
9. Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.
Mennini FS; Marcellusi A; Gitto L; Iannone F
Clin Drug Investig; 2017 Apr; 37(4):375-386. PubMed ID: 28074337
[TBL] [Abstract][Full Text] [Related]
10. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
Hu H; Luan L; Yang K; Li SC
Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
Modena V; Bianchi G; Roccatello D
Autoimmun Rev; 2013 Jun; 12(8):835-8. PubMed ID: 23219766
[TBL] [Abstract][Full Text] [Related]
12. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.
Kvamme MK; Lie E; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2012 Sep; 51(9):1618-27. PubMed ID: 22539479
[TBL] [Abstract][Full Text] [Related]
13. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
14. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
16. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study.
Roodenrijs NMT; Welsing PMJ; van der Goes MC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
Rheumatology (Oxford); 2021 Oct; 60(10):4681-4690. PubMed ID: 33502493
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
18. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
Puolakka K; Kautiainen H; Mottonen T; Hannonen P; Korpela M; Hakala M; Luukkainen R; Vuori K; Blåfield H; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(2):96-103. PubMed ID: 19274516
[TBL] [Abstract][Full Text] [Related]
19. The costs of rheumatoid arthritis.
Allaire SH; Prashker MJ; Meenan RF
Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
[TBL] [Abstract][Full Text] [Related]
20. Trends in economic consequences of rheumatoid arthritis over two subsequent years.
Verstappen SM; Jacobs JW; Kruize AA; Ehrlich JC; van Albada-Kuipers GA; Verkleij H; Buskens E; Bijlsma JW
Rheumatology (Oxford); 2007 Jun; 46(6):968-74. PubMed ID: 17337750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
